Sequent Scientific Limited (BOM: 512529)

Market Cap	48.15B
Revenue (ttm)	14.54B
Net Income (ttm)	164.81M
Shares Out	249.35M
EPS (ttm)	0.66
PE Ratio	292.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,922
Open	193.00
Previous Close	194.85
Day's Range	185.15 - 199.90
52-Week Range	91.85 - 240.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About Sequent Scientific

Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology fo...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 1,195
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 512529

Financial Performance

In 2023, Sequent Scientific's revenue was 13.70 billion, a decrease of -3.60% compared to the previous year's 14.21 billion. Losses were -358.69 million, -70.40% less than in 2022.